Compare BXC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXC | MRVI |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 449.6M |
| IPO Year | 2004 | 2020 |
| Metric | BXC | MRVI |
|---|---|---|
| Price | $59.93 | $3.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $88.67 | $4.58 |
| AVG Volume (30 Days) | 103.7K | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $2,948,840,000.00 | $192,435,000.00 |
| Revenue This Year | $1.54 | N/A |
| Revenue Next Year | $4.30 | $9.04 |
| P/E Ratio | $35.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.71 | $1.67 |
| 52 Week High | $130.06 | $6.21 |
| Indicator | BXC | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 58.96 |
| Support Level | $59.45 | $3.32 |
| Resistance Level | $65.99 | $3.76 |
| Average True Range (ATR) | 3.21 | 0.22 |
| MACD | 0.96 | 0.00 |
| Stochastic Oscillator | 56.93 | 81.00 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.